Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001437749-24-003756
Filing Date
2024-02-12
Accepted
2024-02-12 16:16:49
Documents
59
Period of Report
2023-12-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q inbp20231231_10q.htm   iXBRL 10-Q 1003020
2 EXHIBIT 31.1 CERTIFICATION OF CO-CEOS ex_600430.htm EX-31.1 13555
3 EXHIBIT 31.2 CERTIFICATION OF CFO ex_600431.htm EX-31.2 15165
4 EXHIBIT 32.1 CERTIFICATION OF CO-CEOS PURSUANT TO 18 USC ex_600432.htm EX-32.1 9114
5 EXHIBIT 32.2 CERTIFICATION OF CFO PURSUANT TO 18 USC ex_600433.htm EX-32.2 7187
  Complete submission text file 0001437749-24-003756.txt   5229561

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA inbp-20231231.xsd EX-101.SCH 45634
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE inbp-20231231_cal.xml EX-101.CAL 37930
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE inbp-20231231_def.xml EX-101.DEF 312616
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE inbp-20231231_lab.xml EX-101.LAB 280092
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE inbp-20231231_pre.xml EX-101.PRE 335263
61 EXTRACTED XBRL INSTANCE DOCUMENT inbp20231231_10q_htm.xml XML 892288
Mailing Address 225 LONG AVENUE BUILDING 15 HILLSIDE NJ 07205
Business Address 225 LONG AVENUE BUILDING 15 HILLSIDE NJ 07205 9739260816
INTEGRATED BIOPHARMA INC (Filer) CIK: 0001016504 (see all company filings)

EIN.: 222407475 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 001-31668 | Film No.: 24620138
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)